|1.||Löscher, Wolfgang: 1 article (01/2014)|
|2.||Rundfeldt, Chris: 1 article (01/2014)|
|3.||Skolnick, Phil: 1 article (11/2012)|
|1.||Panic Disorder (Panic Attack)
04/01/1993 - "The efficacy of alpidem in the treatment of panic disorder remains uncertain and requires assessment in a controlled trial."
04/01/1993 - "Alpidem in the treatment of panic disorder."
04/01/1993 - "The effect of alpidem was investigated in an 8-week, open, clinical trial in 13 patients with panic disorder, with or without agoraphobia. "
|2.||Anxiety Disorders (Anxiety Disorder)
02/01/1997 - "Activity on omega 1 receptor subtypes is perhaps not sufficient in order to obtain a true anti-conflict effect and compounds such as alpidem only relieve some of the symptoms of anxiety disorders."
05/01/1990 - "On the therapeutic action of alpidem in anxiety disorders: an overview of the European data."
02/01/1988 - "Pilot study of alpidem, a new nonbenzodiazepine anxiolytic, in the treatment of generalized anxiety disorder."
05/01/1990 - "In a fourth, clinical, study, 24 patients with a DSM III primary diagnosis of generalised anxiety disorder were treated, under double blind conditions, with doses adjusted according to clinical need of either alpidem 25-150 mg daily or lorazepam 1-6 mg daily.(ABSTRACT TRUNCATED AT 250 WORDS)"
07/01/1994 - "Under a double-blind procedure, 122 patients suffering from general anxiety disorders were randomly allocated to either alpidem (50 mg, three times a day) or alprazolam (0.5 mg, three times a day) for six weeks, followed by a two-week placebo withdrawal phase. "
01/01/1991 - "The most common side effects with alpidem and lorazepam were lightheadedness, drowsiness, and daytime tiredness. "
11/01/2012 - "In contrast to the anxioselective profile displayed in preclinical models, compounds such as bretazenil, TPA023, and MRK 409 produced benzodiazepine-like side effects (sedation, dizziness) in Phase I studies, whereas alpidem and ocinaplon exhibited many of the characteristics of an anxioselective in the clinic. "
01/01/1994 - "We report four cases of acute hepatitis and discuss the role of alpidem. "
01/01/1994 - "[Hepatitis induced by alpidem (Ananxyl). "
01/01/1994 - "[A new case of hepatitis after alpidem monotherapy]."
01/01/1993 - "[Fatal subfulminant hepatitis during treatment with alpidem (Ananxyl)]."
02/01/1995 - "[Subfulminant hepatitis caused by alpidem and treated by liver transplantation]."
|5.||Substance Withdrawal Syndrome (Withdrawal Symptoms)
01/01/1991 - "Moreover, treatment with alpidem did not manifest any withdrawal symptoms. "
07/01/1994 - "Typical withdrawal symptoms on the WSCL were also significantly less severe (P = 0.044) in the alpidem group compared with the alprazolam group. "
01/01/1993 - "A comparison of alpidem and placebo in relieving benzodiazepine withdrawal symptoms."
07/01/1994 - "Alpidem may be a valid alternative to current benzodiazepine anxiolytic therapy because it produces fewer and weaker withdrawal symptoms than alprazolam and is better tolerated."
07/01/1994 - "We investigated whether a new non-benzodiazepine anti-anxiety drug, alpidem, produces weaker withdrawal symptoms than alprazolam. "
|4.||7- (1,1- dimethylethyl)- 6- (2- ethyl- 2H- 1,2,4- triazol- 3- ylmethoxy)- 3- (2- fluorophenyl)- 1,2,4- triazolo(4,3- b)pyridazine
|9.||GABA-A Receptors (GABA(A) Receptor)